Skip to content

Clinical trials

Neutropenia trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neutropenia Country / region: United States Clear all

107 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20014
20023
20036
20041
20052
20066
20071
20084
20093
20106
20115
20126
20132
20142
20153
20165
20173
20182
20191
20202
20213
20222
20232
20244
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed86
Recruiting7
Terminated5
Withdrawn4
Unknown status3
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)13
National Cancer Institute (NCI)8
National Institute of Allergy and Infectious Diseases (NIAID)5
Children's Oncology Group4
Pfizer4
Spectrum Pharmaceuticals, Inc4
Alliance for Clinical Trials in Oncology3
EVIVE Biotechnology3
Karius, Inc.3
Memorial Sloan Kettering Cancer Center3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neutropenia107
Leukemia17
Fever15
Thrombocytopenia15
Infections14
Leukemia, Myeloid, Acute13
Breast Neoplasms12
Precursor Cell Lymphoblastic Leukemia-Lymphoma12
Anemia11
Burkitt Lymphoma9

Trials

Showing 1 to 25 of 107. Each trial links to its page on Pharma Observatory.

7 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.